deltatrials
Completed PHASE1 NCT00451880

Study of XL281 in Adults With Solid Tumors

A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL281 Administered Orally to Subjects With Solid Tumors

Sponsor: Exelixis

Conditions Cancer Colorectal Cancer Melanoma Non-small-cell Lung Cancer Papillary Thyroid Cancer
Interventions XL281 famotidine
Updated 6 times since 2017 Last updated: Oct 11, 2011 Started: Feb 28, 2007 Primary completion: Oct 31, 2011 Completion: Oct 31, 2011

Listed as NCT00451880, this PHASE1 trial focuses on Cancer and Colorectal Cancer and remains completed. Sponsored by Exelixis, it has been updated 6 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1

    First recorded

Feb 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Exelixis
Data source: Exelixis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Dallas, United States
  • • Detroit, United States
  • • Nashville, United States
  • • New York, United States
  • • Scottsdale, United States
  • • Tampa, United States